20 Patents
- US124964702025Anti-sars-cov-2-spike Glycoprotein Antibodies and Antigen-binding Fragments
Regeneron Pharmaceuticals, Inc.
0 cites - US124418002025Bispecific Anti-psma X Anti-cd28 Antibodies and Uses Thereof
Regeneron Pharmaceuticals, Inc.
0 cites - 0 cites
- 0 cites
- US122687302025Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders
Regeneron Pharmaceuticals, Inc.
0 cites - US122514402025Anti-sars-cov-2-spike Glycoprotein Antibodies and Antigen-binding Fragments
Regeneron Pharmaceuticals, Inc.
0 cites - 0 cites
- 0 cites
- 0 cites
- US119865112024Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders
REGENERON PHARMACEUTICALS, Inc.
0 cites - US119640162024Combination of IL-4/IL-13 Pathway Inhibitors and Plasma Cell Ablation for Treating Allergy
REGENERON PHARMACEUTICALS, Inc.
0 cites - 0 cites
- US118665032024Methods for Treating Inflammatory Conditions of the Airway or Lungs by Administering Antagonist Monoclonal Antibodies to Interleukin-33 and Interleukin-4 Receptor
Regeneron Pharmaceuticals, Inc.
0 cites - US118209972023Methods and Compositions for the Targeted Modification of a Genome
Regeneron Pharmaceuticals, Inc.
0 cites - US117789952023Genetically Modified Non-human Animals and Methods of Use Thereof
Institute For Research In Biomedicine (IRB)
0 cites - US117320302023Anti-sars-cov-2-spike Glycoprotein Antibodies and Antigen-binding Fragments
Regeneron Pharmaceuticals, Inc.
0 cites - US116978282023Methods and Compositions for Targeted Genetic Modification Using Paired Guide Rnas
Regeneran Pharmaceuticals, Inc.
0 cites - US115763562023Genetically Modified Non-human Animals and Methods of Use Thereof
Institute For Research In Biomedicine (IRB)
0 cites - US115595642023Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders
REGENERON PHARMACEUTICALS, Inc.
0 cites - US115489472023Bispecific Anti-psma X Anti-cd28 Antibodies and Uses Thereof
Regeneron Pharmaceuticals, Inc.
0 cites